NanoString Establishes Netherlands Cancer Institute as a Center of Excellence for Digital Spatial Profiling
June 18 2018 - 8:57AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced that the Netherlands Cancer Institute
will become the first in a series of Centers of Excellence (COE)
for NanoString’s Digital Spatial Profiling (DSP) platform.
The goal of the COE program is to establish a
global network of centers with expertise in distinct research areas
to expand the utility of the DSP platform. Centers of Excellence
will be the first to have access to DSP and an emerging menu of
content. Each COE will establish a consortium of users and conduct
technology workshops to increase awareness of DSP and generate
impactful data demonstrating the utility of highly multiplexed
spatial analysis. The Netherlands Cancer Institute will lead the
European Center of Excellence with specific expertise in clinical
applications and biomarker development on the DSP platform.
“We are excited to lead the DSP Center of
Excellence to develop clinical research applications and identify
novel biomarkers on this platform,” said Dr. Christian Blank, Group
Leader of Immunology at the Netherlands Cancer Institute. “Already
DSP has provided us with independent validation of mechanisms of
relapse following combination immunotherapy in melanoma, and we
believe this partnership will lead to more discoveries in the field
of oncology with the potential to impact the way we think of
treatment.”
“Establishing Centers of Excellence will enhance
the awareness and establish the utility of the Digital Spatial
Profiling platform for clinical research and biomarker
development,” said Chad Brown, senior vice president of sales &
marketing at NanoString. “We look forward to working with Dr. Blank
and the Netherlands Cancer Institute to demonstrate the unique
capabilities of our DSP technology in advance of our full
commercial launch expected in the first half of 2019.”
About the Netherlands Cancer Institute
The Netherlands Cancer Institute is at the
international forefront of cancer care and research for already
more than a century. The unique combination of health care and
scientific research within the same institute offers great benefit
for cancer patients. Specialized cancer care professionals work
together in multidisciplinary teams every day to set up and carry
out treatment plans tailored to the needs of individual patients
because no two tumors are alike. Cancer patients or people
suspected of having cancer can come to our hospital, known as the
Antoni van Leeuwenhoek, to make use of this personal approach and
the state-of-the-art research and treatment facilities. The
research institute employs more than 650 scientists investigating
many aspects of cancer development, diagnosis, treatment and
epidemiology. Scientists at the Netherlands Cancer Institute have
access to state-of-the-art research facilities supporting their
basic, translational and clinical research. This scientific
research could not be carried out without the institutional support
of the Dutch Cancer Society, the Ministry of Health, Welfare and
Sport, the many research grants obtained by our researchers from
(inter)national funding agencies, and the generous donations made
by individuals that support our research program. The Netherlands
Cancer Institute is the only OECI designated Comprehensive Cancer
Center in the Netherlands. For more information please visit our
websites www.nki.nl and www.avl.nl.
About NanoString Technologies, Inc.
NanoString Technologies provides life
science tools for translational research and molecular diagnostic
products. The company's nCounter® Analysis System has been employed
in life sciences research since it was first introduced in 2008 and
has been cited in more than 2,000 peer-reviewed publications. The
nCounter Analysis System offers a cost-effective way to easily
profile the expression of hundreds of genes, proteins, miRNAs, or
copy number variations, simultaneously with high sensitivity and
precision, facilitating a wide variety of basic research and
translational medicine applications, including biomarker discovery
and validation. The company's technology is also being used in
diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature
Assay together with the nCounter Dx Analysis System
is FDA 510(k) cleared for use as a prognostic indicator
for distant recurrence of breast cancer. In addition, the company
collaborates with biopharmaceutical companies in the development of
companion diagnostic tests for various cancer therapies, helping to
realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo,
nCounter and Prosigna are trademarks or registered trademarks of
NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug FarrellVice President, Investor Relations
& Corporate
Communicationsdfarrell@nanostring.comPhone:
206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Apr 2023 to Apr 2024